fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Chlorpromazine

All products: general benefit

Teva-Chlorpromazine · DIN 00232823 · 25 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Chlorpromazine · DIN 00232823 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-03-09 · brand TEVA-CHLORPROMAZINE · ATC N05AA01 CHLORPROMAZINE · form Tablet · route Oral · ingredients CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 25.0 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Chlorpromazine: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2454). What the ministry pays, not the patient.

Ministry pays: $0.2454 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00232823)

Source record
DIN 00232823: Teva-Chlorpromazine Raw flags: sec3=Y Item: 281608009; group id 484; item number 1234; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2454; ministry $0.2454 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00232823 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1294
Interchangeable products
Largactil · DIN 01929917 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (N05A): coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Flupentixol decanoate (Fluanxol Depot): general benefit
  • Flupentixol (Fluanxol): general benefit

18 more in the class list below

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-CHLORPROMAZINE (Chlorpromazine Hydrochloride) is indicated for:  Management of psychotic disorders such as schizophrenia.  Prevention and treatment of nausea and vomiting when other agents are ineffective or unavailable. Geriatrics (> 65 years of age): TEVA-CHLORPROMAZINE is not indicated in elderly patients with dementia. The safety and efficacy of TEVA-CHLORPROMAZINE in patients 65 years of age or older have not been studied (see WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions Box and Special Populations). Pediatrics (< 18 years of age): The safety and efficacy of TEVA-CHLORPROMAZINE in children under the age of 18 have not been studied (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00018580.PDF PM date: not printed or not captured Source product: TEVA-CHLORPROMAZINE; DIN 00232807; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.